Digital health intervention in an innovative and personalized approach to the management of irritable bowel syndrome in Indian patients: A case series
Abstract
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder marked by abdominal discomfort and altered bowel habits. Despite its prevalence, managing IBS remains challenging due to its complex nature. Digital health interventions have emerged as innovative solutions, combining dietary changes, psychological support, and wellness strategies. This case series of seven IBS patients explores the effectiveness of the DailyBloom IBS App in managing IBS through a 14-week program incorporating a low-FODMAP diet, cognitive behavioral therapy, and physical wellness. Patients experienced reduced abdominal pain, bloating, and diarrhea frequency, alongside the improved quality of life, including less anxiety and stress. This case series highlights the potential of digital therapeutics as a complement to conventional care in India. The DailyBloom™ IBS App adopts a structured four-phase approach: discovery (weeks 1–2), elimination (weeks 3–5), reintroduction (weeks 6–11), and sustenance (weeks 12–14). Patients, categorized into IBS subtypes (IBS-constipation, IBS-diarrhea, IBS-mixed, IBS-undefined), were evaluated for symptom progression, management, and outcomes. Findings emphasize the role of digital therapeutics in providing personalized, evidence-based care, marking a significant advancement in IBS management within the digital health landscape promising both symptom relief and lifestyle improvements for patients.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.